Better decisions
Connected development
PhaseV brings advanced statistical, causal, and simulation methods, and AI-assisted workflows into one clinical development platform, so teams can reduce avoidable risk, rework and delays
The problem
Decisions are connected
Tools rarely are
The population you choose shapes the trial design. The design determines where the trial can run. Each approved choice then flows into sites, data, analyses, and documents, and every program competes with others for the same budget and resources. Yet these decisions are usually made in separate tools, by separate teams and vendors, through manual handoffs. Context gets lost, work gets redone, and the cost shows up as delay, avoidable risk, and decisions made on partial information.
The PhaseV platform
One Platform for Connected Clinical Development Decisions
PhaseV links asset strategy, patient response, trial design, operational planning, and study workflows in one modular platform. Each capability answers a focused question, while the evidence, assumptions, and approved choices move forward with the decision instead of being rebuilt at each handoff
Select the question your team needs to answer
What should we pursue?
Portfolio Optimizer
Prioritize indications, combinations, lifecycle paths, transactions, and late-stage investments using causal evidence and explainable probability of success.
Most relevant to
Portfolio Strategy
R&D Leadership
BD and M&A
Investors
How should we design it?
Trial Optimizer
Explore assumptions, compare fixed, adaptive, Bayesian, and customized designs, then optimize the selected path before protocol commitments are locked.
Most relevant to
Biostatistics
Clinical Development
Program Leadership
Where should we run it?
ClinOps Optimizer
Assess eligibility feasibility, build an explainable country and site strategy, and simulate whether the proposed footprint can meet the enrollment plan.
Most relevant to
Clinical Operations
Feasibility
Study Teams
Program Leadership
Who benefits?
Response Optimizer
Separate predictable outcome variation from differential treatment benefit, then translate the result into a clearer patient and development strategy.
Most relevant to
Clinical Development
Program Teams
Biometrics
Translational Medicine
How do we carry decisions into execution?
AI Conductor
Connect approved decisions to protocols, SAPs, data specifications, code, analyses, outputs, and cross-functional review, while keeping experts in control.
Most relevant to
Medical Writing
Statistical Programming
Data Standards
Regulatory
Cross-functional Teams
Why PhaseV
Built differently for clinical development
PhaseV combines the rigor of clinical and statistical expertise with purpose-built, modular software, explainable modeling, and a fit-for-purpose partnership model.
Tech + Clinical domain expertise
Clinical development is not only a software or data-engineering problem. PhaseV combines clinical-trial expertise with statistics, causal inference, machine learning, simulation, optimization, and software engineering.
Modular by design Connect by context
Start with one analysis or workflow. Add capabilities, evidence sources, and integrations when useful, without introducing another disconnected system or forcing a full-platform implementation.
Built around how your team works
PhaseV complements sponsor teams, CROs, and existing systems. Models, dashboards, governance, integrations, deployment, and operating workflows can be configured around the organization rather than a fixed template.
Evidence
Breast Cancer Retrospective Study
Explore anonymized examples across patient strategy, trial design, site strategy, and portfolio decisions.
“This was an amazing collaboration between Enlivex and PhaseV leading to the identification of a higher-responder group to our drug Allocetra in Knee osteoarthritis patients. Amazing team, smart, innovative, dedicated, responsive and pleasant.”
Oren Hershkovitz, Ph.D.
CEO, Enlivex
Rheumatology (Osteoarthritis)
“We worked with PhaseV on one of our recent trials to identify clinically meaningful subgroups using Response Optimizer. Their expertise helped us identify a promising subpopulation that otherwise would not have been detected. They collaborated with our internal teams to ensure the findings drove real value for our development plan.”
Stu Bailey, D.Phil.
SVP Head of Clinical Measurement Sciences, EMD Serono
Immunology (Confidential Program)
“Leveraging PhaseV’s ClinOps Optimizer was a game-changer for us. We identified top-performing sites with proven recruitment success while also achieving geographic and demographic diversity across our trial footprint.”
VP, Clinical Operations
Big Pharma Company
Oncology (Confidential Solid Tumor Program)
“PhaseV’s Portfolio Optimizer helped us uncover and validate new indications to pursue for, guiding our lifecycle management strategy with data-driven confidence.”
SVP, Strategy & Portfolio Management
Big Pharma Company
Metabolic Disease (Confidential Program)
“PhaseV’s Portfolio Optimizer allowed us to draw clear, data-driven connections between biomarkers and clinical outcomes. This deeper understanding of therapeutic relevance has been critical in shaping our development strategy and informing key decisions for future studies, including those with combination arms.”
VP of Biometrics
Big Pharma Company
Kidney Disease
“Through our initial collaboration with PhaseV, we gained an even greater understanding of the effect of PrimeC across multiple patient subgroups. We will apply these insights to optimize the design of our Phase 3 study... We plan to continue to collaborate with PhaseV as we develop our Phase 3 trial.”
NeuroSense
Neurology (ALS)
“PhaseV played a vital role in the analysis of our Phase 3 trial in the US, ORA-D-013-1, for the treatment of type 2 diabetes. The analysis found subpopulations of patients that responded very well to oral insulin.”
Dr. Miriam Kidron
CSO, Oramed
Metabolic Disease (Diabetes)
“Combining our GI expertise with PhaseV’s advanced machine learning capabilities for trial simulation, design, and execution… accelerate success for our sponsors and help address the growing burden of GI diseases more effectively.”
Pierre Gaudreault
CEO, Alimentiv
Gastrointestinal Diseases
“The addition of prospectively collected clinical-grade real world data to phase 2 results… in conjunction with PhaseV’s proven technology is a critical step forward in improving phase 3 oncology trials, helping to bring new therapies to market.”
Michael Pröschel
CEO, iOMEDICO
Oncology (Solid Tumors)
.png)
